Engineered immune cells take on hard-to-treat breast cancer in new trial

NCT ID NCT06251544

Not yet recruiting Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new type of cell therapy for people with metastatic HER2-positive breast cancer that has worsened after standard treatment. Researchers take a patient's own immune cells (T cells), add new genes to help them recognize and attack cancer cells, and return them to the body. The goal is to find a safe dose and see if the cells can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm mammary neoplasms, animal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST TUMOR MALIGNANT NEOPLASM OF BREAST MAMMARY CANCER MAMMARY NEOPLASM MAMMARY NEOPLASMS, HUMAN NEOPLASM, BREAST TUMOR, BREAST

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••